Main Article Content
allergen-specific immunotherapy, subcutaneous immunotherapy, sublingual immunotherapy, allergic asthma, children
To date, the only disease-modifying treatment strategy for allergic rhinitis and asthma is allergen immunotherapy (AIT). There is evidence that AIT improves allergic rhinitis and asthma, such as reducing symptom severity and medication use and improving of quality of life, with a long-lasting effect after the end of the course. The recent clinical trials evidenced AIT effectiveness and safety in allergic asthma. Consequently, the current version of the GINA (Global Initiative for Asthma) guidelines recommend AIT as an add-on therapy for asthma. There is also evidence that AIT may exert preventive activity on the possible progression from allergic rhinitis to asthma in children and the onset of new sensitizations.
2. Licari A, Castagnoli R, Bottino C, Marseglia A, Marseglia G, Ciprandi G. Emerging drugs for the treatment of perennial allergic rhinitis. Expert Opin Emerg Drugs 2016;21:57-67.
3. Ciprandi G, Marseglia GL, Castagnoli R, et al. From IgE to clinical trials of allergic rhinitis. Expert Rev Clin Immunol 2015;11:1321-1333.
4. Brożek JL, Bousquet J, Agache I, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines-2016 revision. J Allergy Clin Immunol 2017;140:950-58.
5. Global Initiative for Asthma. GINA guidelines, 2019. Global Strategy for Asthma Management and Prevention. (2019) Available from http://www.ginasthma.org/
6. Muraro A, Roberts G, Halken S, et al. EAACI guidelines on allergen immunotherapy: Executive statement. Allergy 2018;73:739-43.
7. Bauer CS, Rank MA. Comparative efficacy and safety of subcutaneous versus sublingual immunotherapy. J Allergy Clin Immunol 2014;134:765-765.e2.
8. Ciprandi G, Fenoglio D, Cirillo I, et al. Sublingual immunotherapy: an update on immunologic and functional effects. Allergy Asthma Proc 2007;28:40-43.
9. Shamji MH, Durham SR. Mechanisms of allergen immunotherapy for inhaled allergens and predictive biomarkers. J Allergy Clin Immunol 2017;140:1485-98.
10. Berings M, Karaaslan C, Altunbulakli C, et al. Advances and highlights in allergen immunotherapy: On the way to sustained clinical and immunologic tolerance. J Allergy Clin Immunol 2017;140:1250-67.
11. Akdis CA, Akdis M. Mechanisms of allergen-specific immunotherapy and immune tolerance to allergens. World Allergy Organ J 2015;8:17.
12. Kappen JH, Durham SR, Veen HI, Shamji MH. Applications and mechanisms of immunotherapy in allergic rhinitis and asthma. Ther Adv Respir Dis 2017;11:73-86.
13. Licari A, Castagnoli R, Brambilla I, et al. Biomarkers of immunotherapy response in patients with allergic rhinitis. Expert Rev Clin Immunol 2018;14:657-663.
14. van de Veen W, Wirz OF, Globinska A, Akdis M. Novel mechanisms in immune tolerance to allergens during natural allergen exposure and allergen-specific immunotherapy. Curr Opin Immunol 2017;48:74-81.
15. La Rosa M, Lionetti E, Leonardi S, Salpietro A, Bianchi L, Salpietro C, et al. Specific immunotherapy in children: the evidence. Int J Immunopathol Pharmacol. 2011;24(4 Suppl):69-78.
16. Mastrorilli C, Posa D, Cipriani F, Caffarelli C. Asthma and allergic rhinitis in childhood: what's new. Pediatr Allergy Immunol 2016;27:795-803.
17. Filipovic ID, Caminati M, Kostic G, Filipovic D, Zivkovic Z. Allergen-specific sublingual immunotherapy in children with asthma and allergic rhinitis. World J Pediatr 2016;12:283-90.
18. Cipriani F, Mastrorilli C, Tripodi S, et al. Diagnostic relevance of IgE sensitization profiles to eight recombinant Phleum pratense molecules. Allergy 2018;73:673-682.